دورية أكاديمية
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
| العنوان: | Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05) |
|---|---|
| المؤلفون: | Nadal, Ernest, Rodríguez Abreu, Delvys, Simó, Marta, Massutí, Bartomeu, Juan, Oscar, Huidobro, Gerardo, López, Rafael, Castro, Javier de, Estival, Anna, Mosquera, Joaquín, Sullivan, Ivana, Felip, Enriqueta, Blasco, Ana, Guirado, Maria, Pereira, Eva, Vilariño, Noelia, Navarro, Valentín, Bruna, Jordi |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | American Society of Clinical Oncology (ASCO) |
| سنة النشر: | 2023 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Tumors cerebrals, Càncer de pulmó, Brain tumors, Lung cancer |
| الوصف: | PURPOSEThe Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials.METHODSThis single-arm phase II clinical trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed was given for four to six cycles followed by atezolizumab plus pemetrexed until progression for a maximum of 2 years. The primary end points were to determine the progression-free survival (PFS) rate at 12 weeks and the incidence of grade >= 3 adverse events during the first 9 weeks. Intracranial outcomes were assessed using response assessment in neuro-oncology brain metastases criteria.RESULTSForty patients were enrolled and 22 (55%) were receiving corticosteroids at baseline. The overall 12-week PFS rate was 62.2% (95% credibility interval [CrI], 47.1 to 76.2). The rate of grade 3/4 adverse events during the first 9 weeks was 27.5%. Most neurologic events were grade 1 and 2 but five patients (12.5%) experienced grade 3-4 neurologic events. With a median follow-up of 31 months, intracranial median PFS was 6.9 months and response rate was 42.7% (95% CrI, 28.1 to 57.9). Systemic median PFS was 8.9 months and response rate was 45% (95% CrI, 28.1 to 57.9). The median overall survival (OS) was 11.8 months (95% CI, 7.6 to 16.9) and the 2-year OS rate was 27.5% (95% CI, 16.6 to 45.5).CONCLUSIONAtezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 10 p.; application/pdf |
| اللغة: | English |
| تدمد: | 1527-7755 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1200/JCO.22.02561Test; Journal of Clinical Oncology, 2023, vol. 41, num. 28, p. 4478-4485; https://doi.org/10.1200/JCO.22.02561Test; http://hdl.handle.net/2445/208722Test |
| الإتاحة: | https://doi.org/10.1200/JCO.22.02561Test http://hdl.handle.net/2445/208722Test |
| حقوق: | cc by-nc-nd (c) American Society of Clinical Oncology (ASCO), 2023 ; http://creativecommons.org/licenses/by-nc-nd/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.64049BAD |
| قاعدة البيانات: | BASE |
| تدمد: | 15277755 |
|---|